Performance guarenteed'

Phospho-JNK1/JNK2 (Thr183, Tyr185) Polyclonal Antibody

Product Details	
Size	100 μL
Species Reactivity	Human, Mouse, Rat
Published Species	Rat, Pig, Insect, Non-human primate, Mouse, Human
Host/Isotope	Rabbit / IgG
Class	Polyclonal
Туре	Antibody
Conjugate	Unconjugated
Immunogen	The antiserum was produced against a chemically synthesized phosphopeptide derived from a region of human JNK1 and 2 that contains threonine 183 and tyrosine 185. This region is conserved among many species including mouse, rat, chicken, nematode, fruit fly, and in JNK3.
Form	Liquid
Purification	Antigen affinity chromatography
Storage buffer	Dulbecco's PBS, pH 7.3, with 50% glycerol, 1mg/mL BSA
Contains	0.05% sodium azide
Storage Conditions	-20°C
RRID	AB 2533720

Applications	Tested Dilution	Publications
Immunocytochemistry (ICC)	1:250	1 Publication
Immunofluorescence (IF)	1:250	3 Publications
Immunohistochemistry (IHC)	Assay Dependent	2 Publications
Western Blot (WB)	1:1000	42 Publications
Immunohistochemistry (Paraffin) (IHC (P))	-	1 Publication
Immunoprecipitation (IP)	-	1 Publication
Miscellaneous PubMed (Misc)	-	3 Publications

Product Specific Information

This antibody is reactive to human and rat JNK1 and 2. Other species of JNK1 and 2 have not been tested, and JNK3 (found primarily in neuronal cell lines) has not been detected. The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated JNK1 and 2. The final product is generated by affinity chromatography using a JNK1 and 2-derived peptide that is phosphorylated at threonine 183 and tyrosine 185. Positive controls used: HEK 293 +/- UV irradiation treatment; PC12 cells +/- sorbitol.

1

O Advanced Verification Data



Phospho-JNK1/JNK2 (Thr183, Tyr185) Antibody (44-682G)

Detection of altered subcellular localization of the target protein upon cell treatment demonstrates antibody specificity. IF using anti- JNK1/2 [pT183/pT185] Rabbit polyclonal Antibody (Product # 44-682G), shows translocation of phospho JNK1/2 (pT183/pT185) to nucleus upon treatment with Anisomycin in A549 cells. Cell treatment validation info.

Product Images For Phospho-JNK1/JNK2 (Thr183, Tyr185) Polyclonal Antibody



Phospho-JNK1/JNK2 (Thr183, Tyr185) Antibody (44-682G) in IF

Immunofluorescent analysis of JNK1/2 (pT183/pT185) was done on 70% confluent log phase A549 cells treated with Anisomycin (25 µg/mL for 30 min). The cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.25% Triton[™] X-100 for 10 minutes, and blocked with 5% BSA for 1 hour at room temperature. The cells were labeled with JNK1/2 (pT183/pT185) Rabbit polyclonal Antibody (Product # 44-682G) at 1:250 dilution in 1% BSA and incubated for 3 hours at room temperature and then labeled with Alexa Fluor 488 Goat Anti-Rabbit IgG Secondary Antibody (Product # A-11008) at a dilution of 1:400 for 30 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor 594 Phalloidin (Product # A12381). Panel d is a merged image showing translocation of JNK1/2 (pT183/pT185) to the nucleus upon Anisomycin treatment. Panel e is untreated cells showing cytoplasmic localization. Panel f shows no primary antibody control. The images were captured at 20X magnification.



Phospho-JNK1/JNK2 (Thr183, Tyr185) Antibody (44-682G) in WB

Western blot analysis of JNK1 + JNK2 (pT183 + pT185) was performed by loading 20 µg of HEK-293 (lane1), HEK-293 treated for 5 minutes with 200 mM of Anisomycin (lane2), HEK-293 treated for 20 minutes with UV (lane3), MCF7 (lane4), MCF7 treated for 5 minutes with 200 mM of Anisomycin (lane5), K562 (lane6), K562 treated for 20 minutes with UV (lane7), HeLa (lane8) and HeLa treated for 20 minutes with UV (lane9) cell lysate using Novex®NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX), XCell SureLock Electrophoresis System (Product # El0002), Novex® Sharp Pre-Stained Protein Standard (LC5800), and iBlot® Dry Blotting System (IB21001). Proteins were transferred to a nitrocellulose membrane and blocked with 5% skim milk for 1 hour at room temperature. JNK1 + JNK2 (pT183 + pT185) was detected at ~ 46 and 55 kDa using JNK1 + JNK2 (pT183 + pT185) Rabbit Polyclonal Antibody (Product # 44-682G) at 1:1000 dilution in 5% skim milk at 4°C overnight on a rocking platform. Goat Anti-Rabbit IgG - HRP Secondary Antibody (G21234) at 1:5000 dilution was used and chemiluminescent detection was performed using PierceTM ECL Western Blotting Substrate (Product # 32106).

View more figures on thermofisher.com

53 References

Western Blot (42)

PloS one	Species
Gastric corticotropin-releasing factor influences mast cell infiltration in	Rat
a rat model of functional dyspepsia.	Dilution
"44-682G was used in Western Blotting to delineate the role of the corticotropin-releasing factor system in the	1:1,000
pathogenesis of functional dyspepsia in a rat model."	Year
Authors: Hagiwara SI,Kaushal E,Paruthiyil S,Pasricha PJ,Hasdemir B,Bhargava A	2019
The Journal of biological chemistry	Species
Glucosamine improves survival in a mouse model of sepsis and	Mouse
attenuates sepsis-induced lung injury and inflammation.	Dilution
"44-682G was used in Western Blotting to investigate the effects of glucosamine on septic lethality and sepsis-induced	Not Cited
inflammation using animal models of mice and zebrafish."	Year
Authors: Hwang JS,Kim KH,Park J,Kim SM,Cho H,Lee Y,Han IO	2019

View more WB references on thermofisher.com

Immunohistochemistry (2)

The Journal of investigative dermatology Upregulated RIP3 Expression Potentiates MLKL Phosphorylation- Mediated Programmed Necrosis in Toxic Epidermal Necrolysis. "44-682G was used in western blot to evaluate the role of RIP3 in toxic epidermal necrolysis." Authors: Kim SK,Kim WJ,Yoon JH,Ji JH,Morgan MJ,Cho H,Kim YC,Kim YS	Species Human Dilution Not Cited Year 2015
Gut Critical role of c-jun (NH2) terminal kinase in paracetamol- induced acute liver failure. Authors: Henderson NC,Pollock KJ,Frew J,Mackinnon AC,Flavell RA,Davis RJ,Sethi T,Simpson KJ	Species Mouse Dilution Not Cited Year 2007

More applications with references on thermofisher.com

ICC (1) IF (3) IP (1) Misc (3) IHC (P) (1)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of subability for use in applications regulated by FDA is made. The warranty perioded herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is mereiv jibury is mereiv jibury of apods and does not represent on anyone other than the Buyer. Any model or sample furnished to Buyer is mereiv jibury is mereival tops and quality of goods and does not represent bot anyone other than the Buyer. Any model or sample. No OTHER WARRANTES, EXPRESS OR IMPLED, ARE GRANTABILTY, FITNESS FOR ANY PARTICULAR PURPOSE, ON NON INFRINCEMENT, BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTES To REPUND FOR A REPLACEMENT OF DREPHANE, REPLACEMENT OF OR REPLAY DOF THE NON-CONFORMING PRODUCTS) ANTER EST ON DO BUIGATION THERE IS NO. OTHER WARRANTES OF REPLAY DER NOT DESTAINES OF REPLAY DOF ON BUGGATION THERE IS NO. DETRICT ON REPLAY BUYER'S EXCLUSIVE REMEDY FOR CONFORMING PRODUCTS DURING THE WARRANTES OR REPLACEMENT OF THE NON-CONFORMING PRODUCTS) ANTER THE WARRANTES OR REPLACEMENT OF DREPARE, REPLACE OR REPLAY DOF AN EXCLUSIVE REMEDY FOR CONFORMING PRODUCTS DURING THE WARRANTES OR REPLACEMENT OF DREPARE, REPLACE OR REPLAY DOF AN EXCLUSIVE REMEDY FORCE MAJEURE, (ii) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (iii) USE OF THE PRODUCTS) AN MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (iv) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. UNless otherwise expressly stated on the